

Supplementary Table 2. Multivariate logistic regression analysis with question items to social disadvantages

Question item	Odds ratio (95%CI), p-value		
	Unemployment or unwilling transfer (213/486 cases)	Decrease in income (244/486 cases)	Reduced social positivity (449/486 cases)
1. Insufficient control of symptoms	1.35 (1.11-1.64), 0.0028	1.08 (0.89-1.32), 0.44	1.12 (0.92-1.36), 0.26
2. Depressive state, changes in mood or character after PSL (PSL use, 81% of subjects)	1.05 (0.81-1.36), 0.72	1.02 (0.78-1.34), 0.86	1.17 (0.86-1.58), 0.32
3. Changes in appearance after PSL (PSL use, 81% of 486 subjects)	0.98 (0.79-1.22), 0.86	0.91 (0.73-1.15), 0.44	1.35 (1.04-1.75), 0.026
4. Diabetes mellitus, osteoporosis, cataracta and/or other arteriosclerotic diseases (PSL use, 81% of subjects)	0.97 (0.75-1.26), 0.83	1.34 (1.01-1.79), 0.044	1.08 (0.79-1.49), 0.62
5. Side effects related to non-steroid immunosuppressive agents (CNI use, 53%; AZA use, 5%)	0.86 (0.61-1.22), 0.39	1.03 (0.72-1.48), 0.86	1.17 (0.75-1.83), 0.48
6. Adverse events related to plasmapheresis (28%)	0.90 (0.50-1.65), 0.74	0.74 (0.39-1.41), 0.36	1.08 (0.53-2.22), 0.83
7. Adverse events related to intravenous immunoglobulin (16%)	1.14 (0.57-2.28), 0.72	1.95 (0.71-5.36), 0.19	1.37 (0.49-3.84), 0.55
8. Long-term (>1 month) hospital stay	1.26 (1.06-1.51), 0.0093	1.58 (1.30-1.91), <0.0001	0.79 (0.65-0.95), 0.013
9. Short-term (≤1 week) hospital stay	1.26 (0.90-1.76), 0.17	1.20 (0.83-1.72), 0.33	1.42 (0.97-2.08), 0.07
10. Need to go to the hospital for years	1.34 (1.04-1.73), 0.023	1.17 (0.90-1.51), 0.25	0.79 (0.61-1.02), 0.069
11. Need to take various oral drugs for years	0.77 (0.58-1.02), 0.068	0.91 (0.68-1.22), 0.52	1.14 (0.84-1.55), 0.39
12. Bias for intractable and uncommon diseases from others	1.32 (1.06-1.65), 0.014	0.89 (0.71-1.11), 0.30	1.51 (1.16-1.98), 0.0023

Significant correlations are indicated bold font. AZA, azathioprine; CI, confidence interval; CNI, calcineurin inhibitor; PSL, prednisolone.